How deep does the IMS merger needs to go before QuintilesIMS divests the R&D element and drops being a CRO from their portfolio? R&D is looking more and more like a pure-Novella org these days, so it may have value to be sold as such or as an independent company.
certainly is the trend. PPD is being auctioned off maybe to LabCorp who previously bought out Covance and Parexel announced they will be spending up to 35 million in employee separations costs coming up this year. What's with Trump's meeting with the Pharm execs, announcing phase I and II trials to be eliminated to cut down costs??
